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Trends
Understanding the determinants of
asymptomatic malaria infections, as a
silent driver of transmission, has
become essential for the success of
elimination campaigns.
Transmission intensity, parasite viru-
lence, immune resistance and tolerance
to infection, host genetic factors, preg-
nancy, or comorbidities can potentially
affect the transition between sympto-
matic and asymptomatic infection and
therefore constitute candidate areas for
further research.Review
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With malaria elimination back on the international agenda, programs face the
challenge of targeting all Plasmodium infections, not only symptomatic cases.
As asymptomatic individuals are unlikely to seek treatment, they are missed by
passive surveillance while remaining infectious to mosquitoes, thus acting as
silent reservoirs of transmission. To estimate the risk of asymptomatic infections
in various phases of malaria elimination, we need a deeper understanding of the
underlying mechanisms favoring carriage over disease, which may involve both
pathogen and host factors. Here we review our current knowledge on the
determinants leading to Plasmodium falciparum symptomless infections.
Understanding the host–pathogen interactions that are most likely to affect
transitions between malaria disease states could guide the development of
tools to tackle asymptomatic carriers in elimination settings.Research is needed to understand
how the risk of asymptomatic malaria
changes when transmission is abruptly
interrupted, as well as the timeframes
needed to lose host defenses that
maintain infections at subclinical levels.
Elimination strategies could be guided
by the surveillance of molecular and
immunological biomarkers that mirror
the dynamics of asymptomatic infec-
tions and allow prediction of the risk of
asymptomatic infections in target
populations.
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Peaceful coexistence with the infected host, rarely causing clinical symptoms, is a common but
poorly understood phenomenon that occurs for many human pathogens [1]. Because such
asymptomatic cases of infection occur without eventual overt symptoms, they do not come to
clinical attention, thus representing a large hidden reservoir of active infection that permits their
persistence and eventual spread to other human hosts. This is the case for many malaria infections
in semi-immune individuals from endemic areas, which commonly cause a mild febrile illness or no
apparent symptoms at all, while keeping parasite numbers at low densities [2] (Box 1).
Carriage of asymptomatic malaria (see Glossary) infections, being at the same time difﬁcult to
detect and to manage, has considerable implications for the design and use of malaria elimina-
tion strategies. Symptomless infections that persist during the dry season in areas of seasonal
transmission have been suggested to seed the malaria outbreaks after annual rains when
mosquitoes reappear [3]. Similarly, asymptomatic parasitemia may potentially contribute to
persistence of transmission in low-transmission settings [4]. However, the precise contribution
of asymptomatic malaria to transmission in areas that have achieved substantial reductions in the
malaria burden remains a matter of debate [5], as is the assumption that detecting and targeting
these individuals for radical treatment, as opposed to using mass drug administration
approaches, would be an efﬁcient and effective tactic. Moreover, eradication in Europe, North
America, and other parts of the world using no better diagnostics than microscopy [6] suggest that
key determinants of success might not be ﬁnding the last parasite. From a practical point of view,
the proportion of asymptomatic infections in certain situations and phases of malaria elimination
may impose the need for modiﬁcations of detection methods (active versus passive case
detection) [7] if, for example, symptom-based surveillance at health facilities is insufﬁcient
and mass blood surveys are necessary to inform the design of elimination interventions.296 Trends in Parasitology, April 2016, Vol. 32, No. 4 http://dx.doi.org/10.1016/j.pt.2015.11.015
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Glossary
Active case detection: detection by
health workers of malaria cases at
community and household level in
population groups that are
considered to be at high risk. Active
case detection can be conducted as
fever screening followed by
parasitological examination of all
febrile patients or as parasitological
examination of the target population
without prior fever screening.
Adaptive immunity: also known as
acquired immunity; one of the two
main immune strategies in
vertebrates (the other being the
innate immune system), characterized
by its antigen-speciﬁc nature and
capacity to develop immunological
memory after an initial response to a
pathogen. Adaptive immune
responses can be of two types:
humoral, mediated by antibodies
produced by B lymphocytes; and
cellular, mediated by T lymphocytes.
Antibody-dependent cellular
inhibition (ADCI): occurs by
monocyte-derived mediators such as
TNF/ that are released when FcgRII-
binding antibodies crosslink
monocytes and merozoites. This
mechanism was suggested to
reversibly inhibit the development of
the parasite leading to chronic
carriage of low-density infections in
asymptomatic individuals.
Asymptomatic malaria:
Plasmodium infections that do not
lead to clinical symptoms and
therefore remain undetected by fever-
based surveillance systems. These
infections can still contribute to the
transmission of the parasite in the
population, which makes them
particularly relevant in the context of
malaria elimination.
Chronic carriage: long-term
presence of parasitemia in blood that
is not causing acute or obvious
illness.
Cytoadhesion: ability of erythrocytes
infected by mature stages of
Plasmodium falciparum to bind to
host receptors in the
microvasculature, to platelets
(platelet-mediated clumping), and to
uninfected erythrocytes (rosettes)
leading to parasite accumulation in
vital organs.
Endemicity: degree of malaria
transmission in an area deﬁned by
spleen rate or parasite rate in children
aged 2–9 years: hypoendemic (0–
10%); mesoendemic (10–50%);
Box 1. Asymptomatic Malaria
Malaria is characterized by acute periodic febrile episodes triggered by the rupture of Plasmodium schizont stage-
infected erythrocytes and the release of merozoites into the bloodstream [11]. This cyclical nature of the emergence of
clinical symptoms is what led to the original nomenclature given to the fevers associated with malaria infections (‘tertian’
or ‘quartan’ fever) well before its life cycle was understood. However, asymptomatic malaria infections are common in
humans living in endemic areas [2], even in low-transmission settings [72], with prevalences four to ﬁve times higher than
clinically patent infections. Although asymptomatic cases generally correlate with lower-density infections [73] and lower
rates of infecting mosquitoes [74], the extended longevity of asymptomatic parasitemia expands the risk of transmission
during much of this time and overall it constitutes a high proportion of transmission [74], possibly greater than that derived
from clinical malaria cases [75]. Estimates of the burden of asymptomatic malaria depend on the method used to detect
infecting parasites and the criteria for the deﬁnition of an asymptomatic episode [42]. Disease episodes are commonly
deﬁned by the presence of fever [26], although various additional, nonspeciﬁc symptoms such as headache, myalgia,
arthralgia, and shivering have been also used [42]. However, little is known about the silent or long-term health
consequences of asymptomatic infections. Compared with uninfected individuals, individuals with asymptomatic
infections in Sumba (Indonesia) showed higher levels of inﬂammation markers, von Willebrand factor, and platelet
factor-4 and lower platelet counts and hemoglobin levels [76]. Asymptomatic plasmodial infection has been also
associated with anemia among pregnant women [57] and children [77], as well as with chronic malnutrition [77] and
cognitive impairment among children [78]. Studies that have based estimates of asymptomatic malaria at a particular time
point [42] may misclassify as asymptomatic certain infections that are at an early stage of progression toward
symptomatic disease or in the process of being cleared after antimalarial medication [79]. The few studies that have
looked at such progression over time report a shift between states in only a small proportion of infections [80] and up to
90% of asymptomatic infections [81], probably reﬂecting different epidemiological scenarios. Long-term carriage of
asymptomatic infection is suggested by observations in seasonal transmission settings, where asymptomatic infections
can last several months until the restart of the following transmission season [82,83]. Asymptomatic Plasmodium
falciparum infections among migrants who moved from endemic areas to settle in malaria-free countries can persist for as
long as 8 years [84]. Although mathematical models suggest that P. falciparum can persist for up to 4 years [85], recent
estimates suggest that very short infections, of the order of days rather than weeks, may be more common than
previously thought [86].Deciphering the parasite and host factors contributing to the asymptomatic carriage of malaria
infection can help to predict where and when asymptomatic carriage is most likely to occur. With
a growing need to better understand the silent reservoir of malaria transmission, we here review
what is currently known regarding the host and parasite determinants of asymptomatic infec-
tions. Through the lens of malaria elimination, we aim to highlight potential biological pathways
affecting the transition between malaria disease states that could be exploited for the develop-
ment of tools to tackle asymptomatics in elimination settings.
Determinants of Asymptomatic Malaria
Why some individuals develop clinical manifestations during malaria infection while others remain
asymptomatic is poorly understood. The general state of health and physiological condition of
the host, particularly subtle immunity variations, together with host genetic predisposition and
parasite factors involved in the virulence of the infection might inﬂuence the progression of
malaria infection toward an asymptomatic outcome (Figure 1).
Malaria Parasite Factors
The abilities of malaria parasites to multiply, adhere to host tissues, produce toxic substances, or
elicit deleterious immune responses have been considered attributes of virulence. Differences
noted between Plasmodium falciparum strains and isolates in their maximum parasitemia [8],
pyrogenic thresholds [9], multiplication rates [10], and cytoadhesion leading to seques-
tration in vital organs [11] suggest that there might be parasite factors that contribute to the
development of asymptomatic infection.
Pyrogenic Threshold
All of the clinical symptoms associated with malaria are caused by the asexual erythrocytic or
blood-stage parasites. Lysis of infected erythrocytes releases to the bloodstream not only
merozoites but also parasite byproducts such as hemozoin, glycosylphosphatidylinositolTrends in Parasitology, April 2016, Vol. 32, No. 4 297
hyperendemic (constantly over 50%);
and holoendemic (constantly over
75%).
Glycosylphosphatidylinositol
(GPI): molecules that anchor a
diverse range of proteins to the
surface of malaria parasites and are
thought to function as a toxin that
contributes to severe malarial
pathogenesis.
Hemozoin: insoluble and chemically
inert b-hematin crystals resulting from
the detoxiﬁcation of free heme
produced by the parasite metabolism
in infected erythrocytes.
Immune resistance to infection:
the capacity of the host's innate and
adaptive immune system to reduce
parasite density levels.
Immunopathology: tissue damage
caused by an excessive response of
the immune system against an
infection.
Innate immunity: the nonspeciﬁc
immune system of the organism that
responds to a pathogen infection in a
generic way.
Malaria elimination: permanent
interruption of local mosquito-borne
malaria transmission in a deﬁned
geographical area.
Mass drug administration: strategy
that aims to drastically interrupt
malaria transmission intensity through
the administration of an antimalarial
drug to a speciﬁc target population
regardless of their infection status.
Parasite multiplication rate: rate of
parasite growth and proliferation
during an infection.
Passive case detection: detection
of malaria cases among patients who
on their own initiative went to a
health post for treatment, usually
because of febrile disease.
Pathogen-associated molecular
patterns (PAMPs): small molecular
motifs conserved within groups of
pathogens that are recognized by
cells of the innate immune system
through their TLRs and other PRRs.
Pattern recognition receptor
(PRR): proteins expressed by innate
immune cells for the initial detection
of PAMPs as well as damage-
associated molecular patterns.
Plasmodium falciparum
erythrocyte membrane protein 1
(PfEMP1): a parasite protein that
binds to several host receptors to
mediate the sequestration of infected
erythrocytes.
Plasmodium falciparum sirtuin 2a
(PfSir2a): a transcriptional regulatory
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Figure 1. Host and Malaria Parasite Interactions Resulting in Damage and Disease. Disease is the clinical
manifestation of body damage that results from host–parasite interactions. Damage may be caused directly by malaria
parasites through erythrocyte destruction or sequestration in vital organs or by parasite byproducts (toxins or oxidant
agents such as glycosylphosphatidylinositol or hemozoin). However, damage may also arise as a result of the host immune
response against infection, leading to inﬂammation. Host mechanisms of resistance to infection mediated by the innate and
adaptive immune system can reduce pathogen burden and ameliorate symptoms. Also, damage caused directly by the
pathogen or indirectly by the host immune response can be minimized by immunoregulation, cellular adaptation, or parasite
toxin neutralization irrespective of pathogen burden (i.e., tolerance to malaria infection). Such mechanisms may be
modulated by previous exposure to malaria parasites, leading to adaptive responses, host genetic predisposition to
combat disease, and comorbidities. Identiﬁcation of host and pathogen factors responsible for inﬂuencing the amount of
damage caused during an infection might be used to better characterize the infection outcome at a community level.
Surveillance tools based on these factors might guide the selection of the most effective elimination strategies to target the
asymptomatic reservoir of malaria transmission.(GPI), and other toxic factors. Such products trigger production of pyrogenic inﬂammatory
mediators and cytokines by macrophages and other innate immune cells that in turn stimulate
thermoregulatory regions of the brain to increase body temperature [12]. As parasite density
increases, so does the amount of toxins and pyrogenic mediators, and with them the body
temperature and the risk of fever. The parasite load threshold associated with the onset of fever
in human hosts has been considered a potential indicator of the risk of symptomatic malaria in a
parasite carrier [13]. The ability to trigger a fever may be important for the parasite to regulate its
growth [12], thereby establishing a longer infection that enhances the probability of transmis-
sion. The pyrogenic threshold of P. falciparum malaria infections in non-immune individuals has298 Trends in Parasitology, April 2016, Vol. 32, No. 4
protein that epigenetically regulates
var gene switching.
Premunition: exposure-dependent
acquisition of immunity in which
partially effective responses protect
against illness and high numbers of
parasites in the blood without
completely eliminating the infection.
Pyrogenic threshold: a population-
based statistical measure that deﬁnes
a parasite density above which fever
may occur and below which most
cases are afebrile.
Submicroscopic infection: malaria
infections with parasitemia levels that
are below the microscopic threshold
for detection.
Surveillance: systematic monitoring
of malaria cases and deaths with the
purpose of planning and evaluating
malaria control program as well as
generating an immediate action in
response to case identiﬁcation.
Tolerance to infection: host
defense mechanisms that minimize
the damage caused directly by the
pathogen or indirectly by the host's
immune response irrespective of
pathogen burden.
Toll-like receptor (TLR): proteins
with variable extracellular leucine-rich
repeats mainly present at the
membrane of innate immune cells;
stimulate a proinﬂammatory response
when they recognize structurally
conserved molecules derived from
microbes.
Transmission intensity: rate at
which people living in malaria-
endemic areas are bitten by
anopheline mosquitoes carrying
human malaria sporozoites.
Transmission intensity is often
expressed as the entomological
inoculation rate, which is the average
number of inoculations with malaria
parasites received by one person
during a period of time.
var genes: parasite genes with
extreme inter- and intragenome
variability that encode the PfEMP1
family of proteins in P. falciparum.
Waning of immunity: loss of the
acquired immunological capacity to
control an infection.been shown to cover a wide spectrum of parasite densities ranging from 10 to 200 000
parasites/ml [9], varying as a function of transmission intensity, age, or host ethnicity [9].
In high-transmission areas, clinical illness is not often associated with parasitemia of P.
falciparum below 10 000 parasites/ml [14]. In general, a relationship between increasing P.
falciparum parasite density and fever among children has been reported in high-transmission
areas [14]. However, this has not been demonstrated in other areas with intense seasonality or
in low-transmission settings [15], questioning the reliability of parasite densities in distinguish-
ing malaria attacks from other causes of fever. Moreover, signiﬁcant differences have been
observed between the pyrogenic thresholds for different P. falciparum strains [9], suggesting
that some strains may induce a febrile response in the host at lower parasite densities
compared with other strains. Possible explanations for these differences include variations
in the virulence of the strains in inducing an inﬂammatory response, in their potential for
cytoadhesion and sequestration, in the degree of synchronization of parasite populations,
or in the length of the replication cycle.
Multiplication Rate
The parasite multiplication rate, which has been linked to the severity of disease in P. falciparum
malaria [16], depends on the balance between the intrinsic susceptibility of the host erythrocytes,
the level of antimalarial immunity, and the ability of the parasites to multiply at high densities [17].
As in other eukaryotes, the synthesis of rRNA determines ribosome production and the potential
for parasite growth and proliferation [18]. One candidate molecule to regulate Plasmodium rDNA
transcription is the highly conserved NAD-dependent deacetylase Sir2 [P. falciparum sirtuin 2a
(PfSir2a)], the ﬁrst identiﬁed epigenetic factor shown to be involved in transcriptional control of
antigenic variation in P. falciparum [19]. Metabolic changes in NAD+/NADH and high temper-
atures found in malaria-induced febrile illness have been suggested to modulate PfSir2a activity
[12], balancing the malaria parasite's energy status with rRNA synthesis and parasite prolifera-
tion. Therefore, the epigenetic environment may play an important role in the establishment of
asymptomatic infections and modulate the switch between chronic and acute infection in
response to the host or as part of the parasite developmental program [20]. Moreover, regulation
of genes involved in DNA replication and the unfolded protein response could potentially lead to
dormancy phenotypes in P. falciparum malaria that have been suggested to contribute to
artemisinin resistance [21].
Parasite Cytoadhesion
The virulence of P. falciparum has been linked to the expression of P. falciparum erythrocyte
membrane protein 1 (PfEMP1) on the surface of infected erythrocytes. PfEMP1s bind to
several host receptors to mediate the sequestration of infected erythrocytes in vital organs [11]
and drive inﬂammation by blocking the cytoprotective function of the endothelial protein C
receptor [22]. PfEMP1s are encoded by approximately 60 var genes per parasite genome,
which are expressed in a mutually exclusive manner to avoid simultaneous recognition by the
immune system [11]. Host antibodies against PfEMP1 variants have been suggested to
structure the switch between var genes in a hierarchical process [23], with parasites expressing
conserved and virulent PfEMP1s eventually surpassed by less virulent and more diverse variants
that dominate infections in semi-immune individuals. Despite having extreme inter- and intra-
genome variability, PfEMP1s can be subdivided into three major groups labeled A, B, and C
based on motifs in noncoding sequences and locus position [24]. Group A var genes have been
shown to be preferentially expressed by parasites associated with severe disease syndromes
while greater transcription of var group C has been found in older children with asymptomatic
malaria [25,26]. This differential expression suggests that once the initial var gene repertoire is
exhausted by increasing immunity, var group C, or an alternative, unknown group of var gene
variants that do not mediate cytoadherence in vital organs, might prevail in asymptomatic
infections. Such chronic and asymptomatic malaria infections may survive their encounters withTrends in Parasitology, April 2016, Vol. 32, No. 4 299
the host immune system by generating novel antigenic variants via mitotic recombination at a
very high rate [27].
Multiplicity of Infection and Drug Resistance
Although evidence is far from conclusive, additional parasite-related factors such as drug
resistance or multiplicity of infection have been suggested to differ between malaria disease
states. One study found a signiﬁcantly higher prevalence of drug-resistant parasite strains
among asymptomatic children compared with febrile children [28]. This reduced virulence
among drug-resistant parasites was attributed to a possible ﬁtness loss associated with
the acquisition of mutations mediating antimalarial resistance [29]. However, such an
interpretation contradicts epidemiological evidence from areas of seasonal transmission
where asymptomatic infections persisting during the dry season mostly comprise wild-type
parasites [3]. Another study found that the proportion of mixed-genotype infections and the
number of genotypes per person was higher among asymptomatic than symptomatic
infections and that this diversity of infecting strains might enhance protection against clinical
malaria [30]. Additional evidence has further suggested that multiplicity of genotypes could
also favor the parasite by extending the duration of infections through the selection of
genotypes that ensure parasite survival and transmissibility [31]. Nevertheless, more
research is needed to conclusively afﬁrm an association of these factors with asymptomatic
infections.
Host Defenses
The processes that determine the acquisition of host defenses that allow asymptomatic carriage
of malaria parasites are poorly understood. Hosts can employ two non-mutually exclusive
defense strategies against pathogens. One relies on the capacity of the host's immune system
to reduce pathogen burden (i.e., resistance to infection, which can be measured as the inverse of
the pathogen burden) whereas the other minimizes the damage caused directly by the pathogen
or indirectly by the host's immune response irrespective of pathogen burden (i.e., tolerance to
infection, deﬁned as the slope of host ﬁtness against infection intensity) [32].
Immune Resistance To Malaria
Mechanisms of innate and adaptive immunity can protect the infected host by reducing
malaria parasite load. Immune resistance to sporozoites transmitted by Anopheles mosqui-
toes and exoerythrocytic liver stages is rarely if ever achieved, probably because of the low
inoculum of parasites in the mosquitoes’ saliva and a lack of robust immunity to these stages in
individuals naturally exposed to P. falciparum [33]. By contrast, immunity against blood-stage
parasites determines the course of disease in humans [33] and is acquired at a rate that depends
on the intensity of malaria transmission (Box 2).
Innate immune cells such as monocytes/macrophages, natural killer cells, and gd T cells can
sense early blood-stage infection, inhibit parasite multiplication through the production of pro-
inﬂammatory cytokines and chemokines, and direct the quality of adaptive immune responses
[34]. This initial detection of parasites is mediated by pattern recognition receptors (PRRs)
expressed by immune cells and pathogen-associated molecular pattern (PAMP) mole-
cules in P. falciparum such as GPI, hemozoin, and AT-rich and CpG-containing DNA motifs
bound to hemozoin [33]. Adaptive immune responses against malaria parasites have been
suggested to rely on the exposure-dependent acquisition of antibodies that reduce parasite
growth [17]. This can be achieved through the blocking of critical invasion ligands in the
merozoite, by inhibiting secondary proteolytic processing of such parasite ligands or their
surface redistribution on merozoites or by blocking their interaction with host receptors. Anti-
bodies can also contribute to opsonin-mediated phagocytosis of infected erythrocytes and
antibody-dependent cellular inhibition (ADCI). Finally, antibodies may also target PfEMP1s300 Trends in Parasitology, April 2016, Vol. 32, No. 4
Box 2. Transmission Intensity, Submicroscopic Infections, and Asymptomatic Carriage
The malaria infection history of a host, mainly determined by the intensity of transmission, affects the outcome of
subsequent infections [33]. It has been generally assumed that, in areas of reduced malaria transmission, populations
with little exposure to parasites and thus limited potential for the acquisition of antimalarial immunity will develop high-
density symptomatic parasitemia when infected and seek antimalarial treatment [87]. Conversely, more asymptomatic
infections would be expected in areas of high malaria transmission where individuals can rapidly acquire immunity that
partly restricts parasite growth. Such a correlation between high endemicity, and thus transmission intensity, and high
asymptomatic prevalence has been reported in several African countries, ranging from 20% to 97% in areas of high
transmission compared with less than 10% in areas of low transmission [2,42]. At a microscale, several studies also show
a higher prevalence of asymptomatic carriers in villages of high compared with low malaria incidence [88]. This is in line
with studies showing a reduction in parasite densities with increasing transmission intensity at village level [89] or with
increasing proximity to vector breeding sites [90]. Similarly, the performance of rapid tests has been shown to decline with
increasing transmission intensity [89], suggesting that people living in high-transmission areas may acquire immunity and
control infections to densities below the detection threshold of standard diagnostic techniques. However, the relationship
between transmission and parasite density seen on smaller scales is not observed over larger geographical areas, where
lower endemicity has been related to a larger proportion of submicroscopic infections [73]. Such a high carriage of
infections below the threshold of microscopic detection in areas of low transmission could be explained by the
persistence of residual immunity in areas of low transmission, which keeps parasite density at submicroscopic levels
[5], or fewer infections to overwhelm the immune response. Moreover, reduced parasite diversity in areas of low
transmission may increase the rate of acquisition of immunity, which, combined with fewer opportunities for super-
infection, may allow persistence and thus detection of low-density infections for long periods of time [73]. Finally,
genetically homogeneous infections in areas of low transmission could reduce within-host competition, eventually
selecting for lower levels of virulence [91].involved in parasite cytoadherence and rosetting, eventually preventing their sequestration in
vital organs and leading to their clearance in the spleen [11,33,35].
Despite the apparent importance of antibodies, the role of antibody-mediated immunity for the
transition between clinical disease and asymptomatic infection remains unclear. Several reports
have shown antibody responses against Plasmodium merozoite antigens that predict a reduced
risk of symptomatic malaria and high-density P. falciparum infections, including those against
members of the serine-enriched repeat antigen (SERA) family [36], merozoite protein 4 (MSP-4)
[36,37], MSP-119 [38], and apical merozoite antigen 1 (AMA-1) [39]. Antibodies against PfEMP1
have also been suggested as important contributors to the prolonged chronicity characteristic of
asymptomatic infections, with disease occurring as a result of holes in the antigenic repertoire
recognized by the host [40]. Field studies indicate that cumulative exposure to a variety of diverse
PfEMP1s is required for the transition from symptomatic to asymptomatic malaria [35]. More-
over, carriage of antibodies against PfEMP1 among children with ongoing asymptomatic
infection is associated with protection from future clinical malaria episodes [41]. Overall, these
studies suggest that protection from the onset of febrile malaria may require the acquisition of
broadly reactive IgG antibodies at levels that exceed a protective threshold rather than antibody
titers for individual antigens [38,41]. Although mainly mediated by IgG, other isotypes such as IgE
[42] and polyclonal antibodies [43] have been associated with a reduced risk of developing
clinical malaria, indicating a putative role for these immunoglobulins in pathogenesis. However,
there remains a lack of speciﬁc and validated correlates of immune protection contributing to
asymptomatic malaria.
Similarly to antibodies, it is not fully understood which immune cells mediate clinical immunity
[33]. Research suggests a protective effect for T cell cytokine responses [particularly interferon
gamma (IFN-g)] on the control of parasite replication [33]. Appropriate dendritic cell maturation
and T regulatory cell activation has been described in asymptomatic Plasmodium infection, in
contrast to reduced maturation markers of dendritic cells and an increased proportion of
activated T regulatory cells in acute malaria [44]. Malaria-induced tumor necrosis factor alpha
(TNF/) might also increase T cell regulatory activity and therefore more effectively prevent
inﬂammation [45]. Asymptomatic infection has been inversely associated with the frequency ofTrends in Parasitology, April 2016, Vol. 32, No. 4 301
TNF/-producing CD4+ T cells [46], suggesting that production of this inﬂammatory cytokine
may decrease with increasing cumulative malaria exposure, enabling a transition to asymptom-
atic infection. Overall, these data provide evidence of appropriate immune activation in asymp-
tomatic infection and immune dysfunction in acute clinical malaria. However, the speciﬁc cellular
immune responses involved in the transition to and maintenance of asymptomatic infection
remain unknown.
Both poor induction of immune responses by the parasite and rapid waning of immunity have
been proposed to explain the persistence of chronic low-density malaria infections [33]. There is
mounting evidence that Plasmodium evades humoral immunity through deregulation of T and B
cell function [33]. However, controlled human experimental infection has shown to induce long-
lasting cellular immune responses to malaria parasites, mainly carried within the /b T cell and gd T
cell compartment [47]. Moreover, several studies have now shown that P. falciparum-speciﬁc
memory B cells are generated in response to infection, albeit inefﬁciently, as their prevalence
appears to be relatively low among adults (30–50%) [48]. Once acquired, however, memory B
cells are long lived [48] and persist longer than antibodies in the absence of ongoing P. falciparum
exposure [49]. However, it is unknown whether asymptomatic parasitemia can drive an increase in
memory B cells. Overall, direct evidence for the presence or absence of immune memory to
malaria, and the implications for the asymptomatic carriage of infection, remains limited.
Tolerance to Malaria Infection
In human malaria, most individuals fail to develop true sterilizing immunity and remain vulnerable
to chronic carriage of low-density asymptomatic infections into adulthood [33]. Such a phe-
nomenon, known as premunition, is suggested to result in tolerance to malaria infection.
Infections may remain asymptomatic if major disruptions of physiological functions are pre-
vented by tolerance mechanisms. Such tolerance developed by the host is likely to be multi-
factorial and includes the neutralization of parasite toxins and other virulence factors and
immunoregulatory mechanisms that reduce the damage triggered by excessive immune
responses of the host (i.e., immunopathology) as well as cellular and systemic adaptive
responses that limit the deleterious effects associated with stress imposed by pathogens
and/or host immunity (Box 3).
Tolerance to malaria parasites may be acquired after a single infection, as the pyrogenic
threshold during an infection in non-immune hosts increases between the ﬁrst and second
fever episodes [9]. Moreover, a larger proportion of patients remained asymptomatic during the
reinfection (11.5%) compared with the initial infection (1.8%) [9], suggesting the persistence of
tolerance mechanisms after the infection ends. Malarial tolerance is also thought to be most
efﬁcient in childhood and then decline with age. This is because the threshold of parasitemia
associated with fever appears to be higher in children than in adults from the same malaria-
endemic regions [14]. Thus, children with high parasite densities tend to be more frequently
asymptomatic compared with adults with a similar parasite burden (i.e., can tolerate higher
parasite burdens), while the latter are more efﬁcient in suppressing peripheral parasitemia and
controlling clinical attacks [50]. Taken together, these observations suggest that tolerance
mechanisms contributing to asymptomatic malaria in populations intensely exposed to P.
falciparum can be developed after few infections, persist once the infection is cleared, and
be more effectively inducible in children but, once acquired, more evident in adults.
Host Genetic Factors
Host genetic background can determine the susceptibility to different clinical presentations of
malaria [51]. Genome-wide association studies have indicated a few genetic variants, including
numerous immune system polymorphisms, hemoglobinopathies (HbS, HbC, HbE, thalasse-
mias, Southeast Asian ovalocytosis), and other gene variants linked to the erythrocyte system302 Trends in Parasitology, April 2016, Vol. 32, No. 4
Box 3. Mechanisms of Tolerance to Plasmodium Infection
The mechanisms contributing to disease tolerance and the control of tissue damage remain poorly understood.
However, several adaptive responses have been suggested to operate in the context of tolerance to malaria infections.
Neutralization of Parasite Exoantigens
Parasite toxins such as GPI and hemozoin are released at schizont rupture, enhance inﬂammatory cytokine production
by human monocytes, and lead to fever onset [92]. Antibodies against Plasmodium falciparum GPI ameliorate some toxic
manifestations of murine malaria [93] and can inhibit TNF/ production by mononuclear cells [94]. However, solid
evidence for a clinical effect in humans remains lacking [95].
Production of Anti-inﬂammatory Molecules
Nitric oxide (NO), which has been shown to be produced at higher levels by mononuclear cells in asymptomatic children
[96], can suppress the pathogenesis of severe malaria through induction of heme oxygenase-1 (HO-1), CO production,
and inhibition of T cell activation [97]. However, conﬂicting results have questioned the role for NO in mediating tolerance
[98].
Cellular downregulation of P. falciparum-inducible inﬂammation
Repeated malaria exposure can lead to attenuation of the cell-mediated proinﬂammatory responses through either
dysfunction and/or exhaustion of immune cell subsets that produce proinﬂammatory mediators (e.g., Vd2+ gd T cells [99])
or the expansion of immunoregulatory cells that control inﬂammation (e.g., P. falciparum-speciﬁc CD4+Foxp3 T cells
[100]). It has also been suggested that, similar to endotoxin tolerance, regulation of the Toll-like receptor (TLR)
signaling pathway, which recognizes highly conserved PAMPs, could also induce refractoriness of immune cells to
produce inﬂammatory cytokines after repeated malaria stimulations [33].
Induction of Antioxidant Mechanisms
Cell-free hemoglobin released during the blood stage of Plasmodium infection promotes tissue oxidation and organ
failure [101]. Animal models have shown that HO-1, encoded by the stress-inducible gene Hmox1, can protect the
tissues from the heme toxic effect independently of pathogen load [102]. Such a mechanism could explain the protection
mediated by sickle cell anemia [101].
Metabolic Adaptation to Tissue Iron (Fe) Overload
Infected mammals restrict Fe availability to pathogens by sequestering intracellular Fe within various tissues [103], which
can in turn promote tissue damage and exacerbate disease severity. Expression of the Fe-sequestering protein ferritin H
chain (FtH) is induced in response to Plasmodium infection in humans [104] and has been associated with reduced tissue
damage, probably through ferroxidase activity [105], which limits the production of free radicals and can confer tolerance
to malaria infections.(such as blood group, glucose 6-phosphate dehydrogenase deﬁciency, or ATP2B4 calcium
transporters) [52]. Signiﬁcantly fewer studies have directly addressed the role of host genetic
variants in asymptomatic infections, reporting inconclusive results probably due to the low
power to detect modest effects [42].
Pregnancy
Pregnant women have been identiﬁed as a possible large source of chronic asymptomatic carriage
of parasites compared with men and non-pregnant women [53]. In areas with stable and intense
transmission, malaria in pregnancy has been identiﬁed to be commonly asymptomatic [53], even in
the presence of infected erythrocytes sequestered in the placenta [54]. Recrudescence of
placental parasites can occur up to 187 days after the initial infection [55] and can persist
asymptomatically for several months post-delivery [56]. However, such asymptomatic infections
have been associated with maternal anemia [57], suggesting a silent health impact of these
infections (Box 1). Additionally, the high prevalence of gametocytes reported in Malawian pregnant
women [58], although not conﬁrmed in other studies, suggests their potential relevance as a
reservoir of malaria parasites. Further studies are needed to conﬁrm the contribution of pregnant
women with asymptomatic malaria to the persistence of malaria transmission.Trends in Parasitology, April 2016, Vol. 32, No. 4 303
Comorbidities
The health state of the host is modiﬁed by other, coinfecting organisms thereby complicating our
understanding of the clinical outcome of malaria. Plasmodium-infected individuals with hepatitis
B virus infection were more likely to be asymptomatic and to have lower levels of parasitemia,
possibly through an increase in the production of IFN-g levels induced by viral infection that can
contribute to Plasmodium clearance in the liver [59]. Coinfection with soil-transmitted helminths
may alter susceptibility to clinical malaria by activating TH2 cytokines and immunoregulatory
pathways that downregulate effector functions involved in resistance to malaria [60]. HIV can
also impair lymphocyte functions against malaria infection [61]. Similarly, malnutrition can lead to
atrophy of the thymus, leucopenia, and diminished functional T cells that hamper protective
immunity to malaria [62].
Disease Patterns During Changes of Malaria Transmission
Understanding the determinants and clinical consequences of malaria declines and resurgen-
ces, as well as the timescales for changing disease presentations, has become a priority in the
context of the current goal to eradicate malaria. Several studies have shown a shift in the peak of
acute malaria incidence toward older ages as malaria exposure wanes [14,63], which may
precede changes in the number of episodes and disease spectrum in an area with declining
transmission intensities [64]. These observations illustrate that sustained reduction in exposure
to malaria infection leads to changes in mean age and presentation of disease [65]. Moreover,
increases in parasite density and in the susceptibility to severe disease have been observed in
children [66,67] and pregnant women [68] residing in areas where malaria has declined
substantially. Overall, these studies suggest that, in highly endemic areas, measures that led
to reductions of parasite transmission, and thus immunity, may lead to a change in both the
burden and the clinical spectrum of disease.
Information on the burden and signiﬁcance of asymptomatic malaria infections in areas inﬂu-
enced by intense elimination efforts is very incomplete. Data from various countries and stages of
eradication programs conducted in the 1950s showed asymptomatic infection rates ranging
from 91% in Thailand to 0% after an epidemic investigation of 77 new malaria clinical cases in
Sicily [69,70]. The divergences in the observed proportions suggest a close relation with the
epidemiological conditions in the different regions. In areas where malaria was recently hyper-
endemic and where some residual transmission was still ongoing, the proportion of asymptom-
atic infections was comparatively higher. In areas where malaria was not highly endemic or
where transmission had been interrupted a long time ago (more than 6 or 7 years), the
percentage of asymptomatic infections was low. This would indicate some degree of persis-
tence of the immunity originally acquired under hyperendemic conditions as the chief factor in the
occurrence of asymptomatic infections (Figure 2). However, the speed at which immunity wanesTime
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Figure 2. Drops in Transmission,
Loss of Immunity and Risk of Asymp-
tomatic Malaria. The proportion of
asymptomatic infections may depend on
the speed at which malaria transmission
decreases, with a signiﬁcant reservoir of
asymptomatic carriers expected when the
decrease in transmission is more rapid
than the loss of immunity in a population.
By contrast, the asymptomatic reservoir
would be minimal when transmission
has decreased over many years and peo-
ple have lost all antimalarial immunity.
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Figure 3. The Parasite, the Host, Asymptomatic Infections, and Transmission Intensity. Evidence has suggested
that the carriage of asymptomatic infections may depend on a combination of host and parasite factors mediating immunity
and tolerance mechanisms as well as pathogen virulence. A gradual reduction in transmission intensity reduces the
probability of pathogen–host encounters, leading to a progressive decrease of exposure-dependent defense mechanisms
to resist and tolerate an infection. As host protection weakens, the damage caused by the parasite through its multiplication
in erythrocytes, toxin release, and cytoadhesion is expected to increase. Such dynamics support a transition to a symptom-
based surveillance system when transmission is sufﬁciently low. The speed at which malaria transmission decreases may
affect the rate at which host defenses are lost and the emergence of more virulent host–parasite interactions when no
immunity restricts parasite multiplication. To ensure that this argument still holds during malaria elimination campaigns that
seek to rapidly reduce transmission, interventions should ensure that all parasite reservoirs are tackled to avoid the selection
of low-virulence parasite populations that may disrupt such dynamics.
Outstanding Questions
What is the natural progression of
asymptomatic malaria infections over
time and their potential for evolving into
acute disease?
Does the pace at which malaria trans-
mission declines and immunity is lost
affect the asymptomatic pool of infec-
tion observed in a community?
What is the level of malaria transmis-
sion required to sustain host responses
capable of keeping infections at
asymptomatic levels?
Does clinical immunity develop more
rapidly in low-transmission settings than
in high-transmission regions, where
acquired immunity requires years of
intense transmission to develop?
How long does it take to acquire and
loose immunological resistance and
tolerance to malaria infections?
What is the relative contribution of
immune resistance and tolerance to
the risk of being asymptomatic? Is it
possible to formally disentangle toler-
ance and resistance in human malaria?
To what extent is the heterogeneity in
clinical malaria the result of polymor-
phisms in the host genetic background?
What are the key parasite factors asso-
ciated with asymptomatic carriage of
malaria infections?
Does the immune-structured expres-
sion of var genes allow the identiﬁcation
of PfEMP1 types that can be used as
surrogates of asymptomatic Plasmo-
dium falciparum malaria?
What epigenetic factors modulate par-
asite population dynamics and its path-
ogenic potential?
What is the contribution of pregnancy
and particular comorbidities (HIV infec-
tion, helminthiases, malnutrition) to the
overall burden of asymptomatic
infections?
Can malaria elimination interventions
select for parasite strains that are less
virulent or induce higher tolerance by
the host, allowing them to escape
symptom-based detection methods?in the absence of exposure remains unknown, with some studies suggesting that immunity to
febrile malaria can be rapidly lost whereas others indicate long-lasting immunity, particularly
against the most severe forms of disease [33]. Moreover, other factors cannot be entirely
excluded, such as inherited factors involved in the immune response and the possibility of
selecting asymptomatic strains of parasites in the process of eradication. Information on these
factors is, however, scanty at this stage, and current elimination efforts, particularly those based
on mass drug administration, should be helpful in testing such hypotheses. Knowledge of the
host–pathogen interactions that are most likely to result in asymptomatic malaria, especially in
the face of transitioning epidemiological conditions after effective reductions in malaria trans-
mission (Figure 3), could eventually provide information about the strategies with the greatest
temporal and cost efﬁciencies in achieving desired elimination outcomes.
Concluding Remarks
Malaria elimination programs must include tactics to target asymptomatic reservoirs that can
sustain transmission. As the relative contribution of asymptomatic infections to the overall pool of
infections may change during the course of elimination activities, surveillance and response
strategies should be adapted to the different epidemiological scenarios [71]. However, our
understanding of how malaria transmission, host defenses, and parasite factors interact to
trigger the clinical spectrum of malaria infections remains limited, probably because of the
complexity of factors inﬂuencing the clinical outcome of the infection.Trends in Parasitology, April 2016, Vol. 32, No. 4 305
The renewed transition of focus from malaria control to elimination has triggered a new set of
research questions that were previously not prioritized (see Outstanding Questions). In this
context, prospective and reductionist studies to disentangle host responses operating directly
on the parasite and those by which malaria tolerance may occur [32] could provide clues about
the strategies developed by the human host to reduce the clinical consequences of malaria
infections. On the pathogen side, identiﬁcation of factors modulating parasite population
dynamics and its pathogenic potential could provide insight into the mechanisms favoring
asymptomatic carriage over disease. Importantly, such studies should take into account the
selective pressure of elimination interventions on the parasite population, potentially leading
toward less virulent infection that might remain undetected in the form of asymptomatic
infections. Such knowledge can not only improve the management of different diseases out-
comes but also increase the success of malaria elimination efforts.
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